Clearmind is focusing on developing novel psychedelic compounds primarily for the treatment of alcohol use disorder.
Clearmind
Clearmind has developed 5-Methoxy-2-aminoindane (MEAI), a psychoactive compound that exerts a euphoric alcohol-like experience and a reduced desire to consume alcoholic beverages. At present, Clearmind holds 6 patents with a further 5 pending.
Clearmind Medicine received $6.255 million following a round of funding that closed in June 2021. Shares were priced at CAD 1.25.
Activities
B2B
B2C
Pharmaceutical
Biotech
Drug Discovery
Topics of Interest
Alcohol Use Disorder
Explore more company info with a Tree membership
📰 Weekly newsletter about the business of psychedelics
📈 Extended company information (analyst view, fundraising, revenue numbers)
🪄 Priority company page updates